Medical Device

- Beckman Coulter today announced the launch of its DxU Iris Workcell at the AACC Annual Scientific Meeting & Clinical Lab Expo. The DxU Iris Workcell is a fully automated system that streamlines urinalysis workflow and reduces manual reviews to 4%. The new workcell will be showcased in a live launch event held in the AACC Expo hall, booth 1523, and live streamed via LinkedIn on September 28, 2021 at 12 p.m. EDT 9 a.m. PDT .


A routine urinalysis is one the most frequently ordered tests, representing up to 30% of all samples received in the lab 3 . Many of these samples require a lab technician to perform a manual inspection, which causes workflow disruption and a substantial increase in workload. Whether it is confirming the analyzer's findings or identifying unique particle types, manual microscopic reviews are time-consuming and can take up to six times longer per sample than with an automated system 4 .

Automating the routine urinalysis workflow with the DxU Iris Workcell reduces sample subjectivity and variability, helping laboratories of all sizes standardize processes, drive faster turnaround time and deliver quality results.

"There is no doubt that the pandemic has intensified pressure on the clinical laboratory," said Dr. Peter Soltani , senior vice president & general manager, hematology, urinalysis & workflow information technology solutions at Beckman Coulter. "In this pressurized environment, manual reviews are particularly onerous because they are labor-intensive, taking time and focus away from scientific work. We designed the DxU Iris Workcell to allow urinalysis operators to automatically classify sediment particles, minimizing the need for human intervention."

The DxU Iris Workcell pairs the DxU 850m Iris or DxU 840m Iris urine microscopy analyzer with the Arkray AUTION MAX™ 4030 urine chemistry analyzer to create a scalable, fully automated urinalysis solution. The workcell was developed with proprietary Digital Flow Morphology technology with Auto-Particle Recognition (APR) Software to enable laboratories to deliver standardized results using artificial intelligence (AI). This industry-leading technology isolates, identifies and characterizes urine particles to provide immediate, accurate and reproducible results verified directly on the screen.

"As a Med Tech, it's important for me that any new analyzer we bring into the lab makes the workflow better and is easy to use with minimal maintenance. The DxU Iris has several features that can help med techs work more efficiently. One such feature is that the user guide with the key reference information is on the main screen," said Jennifer Soria , a hematology section coordinator for a medical group in Florida . "I love the new Load and Unload station as it can hold multiples racks, allowing users to work in other areas of the lab while processing urine samples."

The DxU Iris Workcell is designed for high-volume laboratories and features:

  • An optional Load and Unload station that increases the capacity of racks for a total of 190 onboard samples
  • Intuitive software user interface to comfortably navigate the analyzer menu, access key reference information and simplify user training in a format aligned across multiple Beckman Coulter instruments including hematology, chemistry and immunoassay
  • Connectivity with Beckman Coulter's advanced informatics software solutions: PRO Service remote service tool, DxONE Command Central remote monitoring, and REMISOL Advance middleware

To learn more about Beckman Coulter's DxU Iris Workcell and other urinalysis solutions, visit the website at www.beckmancoulter.com/DxUIris .

Members of the media can access the online press kit for the DxU Iris Workcell, including videos, images, and other assets at www.beckmancoulter.com/DxUIris-Media .

About Beckman Coulter
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory's role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing and found in hospitals, reference laboratories, and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes, and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics, and unlocking hidden value through performance partnership. A subsidiary of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter, Inc. is headquartered in Brea, Calif. , and has more than 11,000 global associates working diligently to make the world a healthier place.

© 2021 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 2021-9662

ARKRAY, the stylized logo, and the ARKRAY products mentioned herein are trademarks or registered trademarks of ARKRAY in the United States .

REMISOL Advance is a trademark or registered trademark of Normand-Info SAS in the United States and other countries. Used under license.

References:
1 Broadlawns Medical Center. (2019). Manual microscopy divided by on-screen microscopic verification report generated December 20, 2019 . A case study published by Beckman Coulter. https://media.beckmancoulter.com/-/media/diagnostics/products/urinalysis/docs/ua-broadlawns-case-study.pdf .
2 Beaufort Memorial Urinalysis Workflow Case Study, CS-52048.
3 Delanghe, J., & Speeckaert, M. (2014). Preanalytical requirements of urinalysis. Biochemia Medica, 24(1), 89–104. https://doi.org/10.11613/BM.2014.011
4 https://www.mlo-online.com/home/article/13004799/automated-urinalysis-in-the-clinical-lab [Accessed: August 2, 2021 ]

DxU Iris Workcell

DxU Iris Workcell

DxU Iris Workcell

Beckman Coulter logo. (PRNewsfoto/Beckman Coulter)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/beckman-coulters-new-urinalysis-solution-improves-laboratory-workflow-by-significantly-reducing-manual-reviews-to-41-and-cutting-sample-processing-time-by-up-to-782-301386105.html

SOURCE Beckman Coulter Diagnostics

News Provided by PR Newswire via QuoteMedia

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or "the Company") is pleased to announce it placed No. 22 on the 2022 Report on Business ranking of Canada's Top Growing Companies.

Canada's Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 1,850%.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada

- RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), are pleased to announce that RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older. 1

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
person using high-tech ipad

Health is Wealth: The Point-of-Care Health Technology Model

To say the past few years have been a transformative time for healthcare would be putting it lightly.

Care providers all over the world continue to embrace the healthcare industry-wide digital transformation. We’ve seen the rise of transformative new technologies and the creation of new care models — all with one goal in mind: promoting and achieving better patient outcomes. Add to that the evolving role of pharmacies as a critical location for deploying point-of-care testing, and it’s clear why this innovative model is rapidly catching on.

Already a US$1.7 trillion business globally, the pharmacy sector is transitioning from a dispensation model of care to a more profitable, successful, patient-focused services model — supporting the growth of point-of-care technology in the process.

Keep reading...Show less

Medtronic announces closing of public offering of Euro3.5 billion of senior notes

Medtronic plc (the "Company") (NYSE: MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ( "Medtronic Luxco") has closed a registered public offering (the "Offering") of €500,000,000 principal amount of 2.625% Senior Notes due 2025, €1,000,000,000 principal amount of 3.000% Senior Notes due 2028, €1,000,000,000 principal amount of 3.125% Senior Notes due 2031 and €1,000,000,000 principal amount of 3.375% Senior Notes due 2034 (collectively, the "Notes"). All of Medtronic Luxco's obligations under the Notes are fully and unconditionally guaranteed by the Company and Medtronic, Inc., a wholly-owned indirect subsidiary of Medtronic Luxco, on a senior unsecured basis.

The net proceeds from the Offering are approximately €3.47 billion, after deducting underwriting discounts and commissions and estimated expenses related to the Offering payable by Medtronic Luxco. The net proceeds of the Offering are expected to be used to repay at maturity Medtronic Luxco's outstanding 0.00% Senior Notes due 2022, 0.375% Senior Notes due 2023 and 0.00% Senior Notes due 2023 and for general corporate purposes. While Medtronic Luxco may elect at a later date to repay, redeem or repurchase such notes prior to maturity, it currently has no intention to repay, redeem or repurchase such notes prior to maturity.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Danaher Schedules Third Quarter 2022 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2022 on Thursday, October 20, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com , under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic receives FDA clearance for expanded indication of LINQ II insertable cardiac monitor for use in pediatric patients ages 2 and older

The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Monitor (ICM) system is the first-and-only ICM to receive 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×